Jiangsu Hengrui Medicine
600276.SS
#433
Rank
S$63.74 B
Marketcap
$9.67
Share price
-2.55%
Change (1 day)
18.65%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2025 (TTM): S$1.44 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are S$4.04 Billion. In 2024 the company made an earning of S$1.28 Billion, an increase over its 2023 earnings that were of S$0.85 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) S$1.44 B12.39%
2024 S$1.28 B50.69%
2023 S$0.85 B11.4%
2022 S$0.76 B-13.65%
2021 S$0.88 B-34.21%
2020 S$1.34 B15.95%
2019 S$1.15 B33.03%
2018 S$0.87 B20.89%
2017 S$0.72 B23.89%
2016 S$0.58 B11.21%
2015 S$0.52 B39.5%
2014 S$0.37 B20.61%
2013 S$0.31 B11.46%
2012 S$0.27 B29.7%
2011 S$0.21 B31.16%
2010 S$0.16 B27.92%
2009 S$0.12 B5.8%
2008 S$0.12 B79.95%
2007 S$67.35 M32.89%
2006 S$50.68 M38.19%
2005 S$36.67 M21.56%
2004 S$30.17 M13.95%
2003 S$26.47 M38.06%
2002 S$19.17 M